In addition, a vaccine encoding six protamine-formulated prostate cancer-specific antigens (PSA, prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), 6-transmembrane epithelial antigen of prostate (STEAP), PAP and MUC1) was investigated in a phase I/II trial in patients with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (NCT01817738) [42–44]. The gene discussed is FOLH1; the disease is prostate carcinoma.